AR064863A1 - FUSION PROTEIN - Google Patents

FUSION PROTEIN

Info

Publication number
AR064863A1
AR064863A1 ARP080100128A ARP080100128A AR064863A1 AR 064863 A1 AR064863 A1 AR 064863A1 AR P080100128 A ARP080100128 A AR P080100128A AR P080100128 A ARP080100128 A AR P080100128A AR 064863 A1 AR064863 A1 AR 064863A1
Authority
AR
Argentina
Prior art keywords
fusion protein
antigen
fusion
proteins
fusion proteins
Prior art date
Application number
ARP080100128A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0701262A external-priority patent/GB0701262D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR064863A1 publication Critical patent/AR064863A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan proteínas de fusion que comprenden un antígeno derivado de NY-ESO-1 enlazado con un antígeno de LAGE-1, los cuales pueden comprender además vehículos, componentes de fusion, o similares. También se proporcionan métodos para la preparacion, formulacion, y uso de estas proteínas de fusion. Tales proteínas son utiles como componentes de vacuna para inducir una respuesta inmune contra un rango de células que llevan antígeno de cáncer.Fusion proteins are provided comprising an NY-ESO-1 derived antigen bound with a LAGE-1 antigen, which may further comprise vehicles, fusion components, or the like. Methods for the preparation, formulation, and use of these fusion proteins are also provided. Such proteins are useful as vaccine components to induce an immune response against a range of cells that carry cancer antigen.

ARP080100128A 2007-01-15 2008-01-11 FUSION PROTEIN AR064863A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
GB0701262A GB0701262D0 (en) 2007-01-23 2007-01-23 Vaccine
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30

Publications (1)

Publication Number Publication Date
AR064863A1 true AR064863A1 (en) 2009-04-29

Family

ID=39636996

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100128A AR064863A1 (en) 2007-01-15 2008-01-11 FUSION PROTEIN

Country Status (4)

Country Link
AR (1) AR064863A1 (en)
AU (1) AU2008206463B2 (en)
CL (1) CL2008000103A1 (en)
PT (1) PT2118128E (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362715T3 (en) * 2000-03-30 2011-07-12 Dendreon Corporation COMPOSITIONS AND METHODS FOR DIVERTIC CELL-BASED IMMUNOTHERAPY.
EP1708741B1 (en) * 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof

Also Published As

Publication number Publication date
AU2008206463A1 (en) 2008-07-24
PT2118128E (en) 2013-01-29
CL2008000103A1 (en) 2008-07-18
AU2008206463B2 (en) 2013-04-04

Similar Documents

Publication Publication Date Title
CY1125392T1 (en) COMPOSITIONS AND METHODS OF PROTEINS
CO6531481A2 (en) LINK PROTEINS TO THE ANTIGEN IL-23 HUMANS
CR20180027A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER.
CR20170419A (en) NEW PEPTIDES AND NEW COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER CANCER AND OTHER TYPES OF CANCER.
ECSP13012436A (en) BETA AMILOID ANTI-N3pGlu PEPTIDE ANTIBODIES AND USES OF THE SAME
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
GT201700131A (en) COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING BMP6
CL2017001217A1 (en) Antibody drug conjugates.
CR20120310A (en) NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR AND THERAPEUTIC USE
HN2011000357A (en) COMPOSITIONS AND METHODS FOR ANTIBODIES THAT ARE DIRECTED TO COMPLEMENT PROTEIN C5
CL2013001107A1 (en) Polypeptide derived from il-2 with agonist activity; fusion protein that comprises it; pharmaceutical composition that includes it; and its use to treat cancer and chronic infectious diseases.
BR112013018399A2 (en) anti-il1rap antibodies and their uses for human treatment.
AR076655A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO THE COMPLEMENT PROTEIN C3B
BRPI1013780A2 (en) compositions for immunization against staphylococcus aureus.
ECSP13012440A (en) ANTI-FAP ANTIBODIES AND METHODS OF USE
CL2012001030A1 (en) Immunomodulatory polypeptide derived from il-2 comprising several mutations to the native il-2 sequence that preferentially inhibits the activity of il-2 on regulatory t cells in vitro; fusion protein comprising it; and its use to treat cancer.
BR112012021576A2 (en) stable antibody-containing compositions.
DOP2014000083A (en) IMMUNO LINKERS AGAINST TNF
CO6351748A2 (en) ANTIBODIES AGAINST IL-6 AND ITS USES
CL2019000019A1 (en) Antibodies with low immunogenicity and use thereof
BR112017023131A2 (en) anti-fnc antibodies
CL2018001334A1 (en) Antibodies and anti-5t4 antibody-drug conjugates.
UY33274A (en) BASIGIN UNION PROTEINS
SV2016005264A (en) TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND USE OF THESE
EA200900738A1 (en) SLIP PROTEINS CONTAINING ANTIGENS OF TUMOR TENSIONS NY-ESO-1 AND LAGE-1

Legal Events

Date Code Title Description
FB Suspension of granting procedure